Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Iron III Hydroxide Polymaltose Complex
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Scotmann Pharmaceuticals | The Searle Company Limited Pakistan
Deal Size : Inapplicable
Deal Type : Inapplicable
Hypoferritinemia Without Anemia Among Reproductive Age Females
Details : Iron III Hydroxide Polymaltose Complex is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypoferritenemia Without Anemia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 31, 2024
Lead Product(s) : Iron III Hydroxide Polymaltose Complex
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Scotmann Pharmaceuticals | The Searle Company Limited Pakistan
Deal Size : Inapplicable
Deal Type : Inapplicable